Clinical Trial

MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1)

Study acronym: MODUCIN1
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
MODUCIN-1 (MODUcare for CIN1) is a prospective, single center, open-label, randomized trial that its purpose is to compare MODUCARE versus Wait-and-See Approach for the regression rate of histologically proven low-grade Cervical Intraepithelial Neoplasia (CIN1).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-25.
Trial Details
NCT Number NCT07379905
Lead Sponsor Aristotle University Of Thessaloniki
Collaborators: INPA S.A.
Conditions Low-grade Cervical Intraepithelial Neoplasia, Moducare
Enrollment 182 participants
Start Date 2026-03-01
Primary Completion 2027-09-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-05